|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
TuesdayTeva faces considerable uncertainty![]() Whether or not competition emerges is crucial, forcing Teva to put out two sets of guidance for 2014. But, assuming Copaxone faces at least two competitors, Teva thinks 72% of patients could stick with its daily drug or switch to its as-yet-unapproved thrice-weekly formulation. READ MORE |